Ocugen (OCGN) Reports Q1 Loss of $0.04/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Ocugen Provides Business Update and First Quarter 2021 Financial Results
May 7, 2021 7:30 AM EDTConference Call and Webcast Today at 8:30 a.m. ET
COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization)Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN$100.0Â million in gross proceeds raised through a registered direct offering of common stockKey talent acquired representing an instrumental step to position Ocugen for future growthMALVERN, Pa., May 07, 2021 (GLOBE... More
